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Objective. HLA–B27 forms misfolded heavy chain
dimers, which may predispose individuals to inflamma-
tory arthritis by inducing endoplasmic reticulum (ER)
stress and the unfolded protein response (UPR). This
study was undertaken to define the role of the UPR-
induced ER-associated degradation (ERAD) pathway in
the disposal of HLA–B27 dimeric conformers.
Methods. HeLa cell lines expressing only 2 copies
of a carboxy-terminally Sv5-tagged HLA–B27 were gen-
erated. The ER stress–induced protein ER degradation–
enhancing -mannosidase–like protein 1 (EDEM1)
was overexpressed by transfection, and dimer levels
were monitored by immunoblotting. EDEM1, the UPR-
associated transcription factor X-box binding protein 1
(XBP-1), the E3 ubiquitin ligase hydroxymethylglutaryl-
coenzyme A reductase degradation 1 (HRD1), and the
degradation-associated proteins derlin 1 and derlin 2
were inhibited using either short hairpin RNA or
dominant-negative mutants. The UPR-associated ERAD
of HLA–B27 was confirmed using ER stress–inducing
pharamacologic agents in kinetic and pulse chase
assays.
Results. We demonstrated that UPR-induced ma-
chinery can target HLA–B27 dimers and that dimer
formation can be controlled by alterations to expression
levels of components of the UPR-induced ERAD path-
way. HLA–B27 dimers and misfolded major histocom-
patibility complex class I monomeric molecules bound
to EDEM1 were detected, and overexpression of
EDEM1 led to inhibition of HLA–B27 dimer formation.
EDEM1 inhibition resulted in up-regulation of HLA–
B27 dimers, while UPR-induced ERAD of dimers was
prevented in the absence of EDEM1. HLA–B27 dimer
formation was also enhanced in the absence of XBP-1,
HRD1, and derlins 1 and 2.
Conclusion. The present findings indicate that
the UPR ERAD pathway can dispose of HLA–B27
dimers, thus presenting a potential novel therapeutic
target for modulation of HLA–B27–associated inflam-
matory disease.
HLA–B27 is strongly associated with a group of
inflammatory arthritic conditions known as the spondy-
loarthritides, with ankylosing spondylitis (AS) represent-
ing the prototypical presentation (1,2). Up to 90–95% of
patients with AS are positive for HLA–B27, but despite
the fact that this genetic association has been known for
almost 4 decades, the disease mechanism remains poorly
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understood. Genome-wide genetic screening studies
have identified a number of other genes contributing to
AS, but none have yet fully explained the disease process
(3). One current theory linking HLA–B27 to AS involves
the predisposition of HLA–B27 heavy chain to misfold
and form non-native heavy chain dimeric structures (4).
HLA–B27 dimers have been correlated with disease in
the rat model of spondyloarthritis (5). Dimers may
interact aberrantly with immunoreceptors at the cell
surface or act within the environment of the endoplas-
mic reticulum (ER) to induce cellular stress responses,
potentially leading to the onset of proinflammatory
responses (6,7).
Major histocompatibility complex (MHC) class I
molecules present unique protein folding challenges to
the ER quality control machinery, and HLA–B27 is
particularly prone to misfolding, forming disulfided
bonded dimers (8). Misfolding proteins within the ER
can induce the unfolded protein response (UPR), which
is a cellular stress response initiating transcriptional
changes whose function is to restore ER homeostasis
(9,10). There are 3 main effector molecules of the UPR:
activating transcription factor 6, inositol-requiring en-
zyme 1 (IRE-1), and PERK, which reside within the
ER. All are maintained in an inactive state by the
ER-resident chaperone BiP (10–12). One of the most
potent transcriptional changes induced by the UPR
occurs following the oligomerization and autophos-
phorylation of IRE-1. Phosphorylated IRE-1 can splice
cytosolically located X-box binding protein 1 (XBP-1)
messenger RNA by excising a 26-nucleotide intronic
sequence, generating the transcription factor XBP-1
spliced (XBP-1s) (13). XBP-1s can activate chaperones
to enhance cellular folding capacity and/or proteins
involved in degradation of misfolding substrates (14).
ER degradation–enhancing -mannosidase–like
protein 1 (EDEM1) was originally cloned as an ER
stress–induced gene (15), which is targeted by XBP-1s
(14). EDEM1 overexpression studies have demon-
strated a role of this protein in the degradation of
misfolded proteins. EDEM1 is thought to handle mis-
folded proteins in concert with the ER chaperone cal-
nexin and the UPR-induced XBP-1 target E3 ubiquitin
ligase hydroxymethylglutaryl-coenzyme A reductase
degradation 1 (HRD1)–suppressor of Lin12–like 1 (SEL1)
complex (16–18). Together with the E2 ubiquitin–
conjugating enzyme UBE2J1 they were shown to par-
ticipate in the degradation of misfolded MHC class I
heavy chains at steady state (19). Very recently, a role of
EDEM1 in the MHC class I pathway has also been
demonstrated (20), although its interaction with HLA–
B27 was not investigated.
In the current study we demonstrated that
EDEM1 participates in the degradation of HLA–B27
dimers under conditions of ER stress. This degradation
pathway requires XBP-1 and HRD1. Of note, our data
indicate that the ER stress–induced ERAD pathway is a
potential route for therapeutic intervention in HLA–
B27–associated diseases.
MATERIALS AND METHODS
Cell lines and antibodies. Cells were maintained in
Dulbecco’s modified Eagle’s medium (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS; Globepharm) and
penicillin/streptomycin (D10 media) and maintained in a 5%
CO2 37°C incubator. The Invitrogen Flp-In system was used to
generate isogenic HeLa lines stably expressing HLA class I
constructs. HeLa cells with 2 integrated copies of the pFRT/
lacZeo plasmid were identified by Southern blot analysis.
Clone H2Z was -galactosidase positive and Zeocin resistant.
HLA class I constructs for expression were cloned into the
pEF5/FRT/V5-D-TOPO vector. The relevant Flp recombinase
target site–containing expression plasmid was cotransfected,
together with the Flp recombinase-expressing plasmid pOG44,
into H2Z cells and selected using hygromycin B. Recombinants
were identified by the lack of -galactosidase expression and
Zeocin sensitivity, thus generating stable isogenic lines con-
taining 2 copies of HLA class I expression constructs driven
by the human elongation factor 1 promoter or cytomegalo-
virus promoter. The following antibodies were used: anti-V5
(pK; Serotec), anti-FLAG, anti-EDEM1, and horseradish
peroxidase (HRP)–conjugated anti-rabbit monoclonal anti-
body (Sigma), and HRP-conjugated goat anti-mouse antibody
(Dako). Antibodies ME1 (detecting conformational-specific
HLA–B27) and 4E (detecting HLA–B35) were kind gifts from
Dr. J. Neefjes (Amsterdam, The Netherlands) and P. Lehner
(Cambridge, UK), respectively.
Transient transfection. HeLa and HEK 293T cells
were plated at 1  105 and 5  105 cells/well, respectively,
and transfected with complementary DNA (cDNA) expres-
sion constructs and JetPrime PEI (Polyplus Transfection) or
FuGene (Promega), respectively, according to the recommen-
dations of the manufacturers.
Immunoprecipitation and immunoblotting. For
EDEM1 immunoprecipitation experiments, HeLa cells ex-
pressing HLA–B*27:05 were transfected with FLAG-tagged
EDEM1, incubated with 20 mM N-ethylmaleimide/phosphate
buffered saline (NEM/PBS; pH7.4), lysed in 1% digitonin lysis
buffer, immunoprecipitated with anti-FLAG antibody, and
washed in 1% digitonin buffer. For analysis of EDEM1 binding
to MHC class I molecules, 293T cells cotransfected with
EDEM1-FLAG and HLA class I molecules were treated with
20 mMNEM, lysed in 1% Nonidet P40 (NP40) lysis buffer, and
immunoprecipitated with anti-FLAG antibody.
For immunoblotting, samples were resolved by non-
reducing sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE), transferred onto nitrocellulose (BA85;
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Schleicher & Scheull), blocked for 1 hour with 5% skim milk
powder in PBS/0.1% Tween, and then incubated with anti-
bodies. Images were revealed by chemiluminescence using
SuperSignal Femto reagents (Pierce).
Knockdown analysis. For XBP-1 knockdown, trans-
ductions with short hairpin RNA (shRNA)–expressing lenti-
viral vector (pCSBX/pIG) targeting XBP-1 (shXBP-1) were
performed as previously described (21). An equivalent control
vector expressing an shRNA targeting luciferase (shLuc) was
generated using the same methodology. HEK 293T cells were
transfected with p8.91, pMDG, and the shRNA-expressing
lentiviral vector genome, using FuGene 6. Samples showing
high levels of viral transduction (90% green fluorescent
protein positive by fluorescence-activated cell sorting) were
processed and immunoblotted. For HRD1 and EDEM1
knockdown, previously described 19-mer oligonucleotides
matching HRD1 cDNA (19) or EDEM1 cDNA (22) were
incorporated into DNA oligos that were cloned into pSIREN-
RetroQ shRNA expression vector (Clontech) and sequence
verified. HEK 293T cells were transfected with plasmids
encoding Moloney murine leukemia virus Gag-Pol (pCMVi),
vesicular stomatitis virus G Env (pMDG), and pSIREN-
RetroQ–shHRD1 or shEDEM1 to produce pseudotyped
virus-like particles. Supernatants were harvested 48 hours after
transfection.
Chemical inhibitor, ER stress induction, and dimer
half-life assays. HeLa cells expressing HLA–B*27:05 were
incubated at 1  105 cells/well with various concentrations of
kifuensine (KIF; Calbiochem) or DMSO as control and har-
vested 18 hours later. HeLa–B27 cells were incubated with
various concentrations of tunicamycin (TUN), thapsigargin
(TPG), and MG132 for ER stress studies or with 50 M
cycloheximide for half-life analyses. Equal numbers of cells
were harvested, treated with NEM, and lysed in 1% NP40 lysis
buffer. Protein loading was normalized by cell number or MTT
assay.
Monocyte-derived dendritic cells (DCs) and quantita-
tion. After full local ethics committee review/approval and
informed consent were obtained, peripheral blood mono-
nuclear cells were isolated by centrifugation of whole blood
over Histopaque (Sigma). Monocytes adhered to plastic for
2 hours (in RPMI/10% FBS) were cultured with 50 ng/ml
Figure 1. HLA–B27 expression and maturation in HeLa cells. A, HLA–B27 and HLA–B35 are expressed efficiently at the cell surface.
HeLa–B27.Sv5 and HeLa–B35.Sv5 cells were analyzed by flow cytometry with antibodies ME1 and 4E, respectively. HeLa–B27 cells, HeLa–B35
cells, and mock-transfected controls (E84) expressed antibody W632–reactive major histocompatibility complex (MHC) class I molecules. B,
Quantitation of HLA–B alleles using HC10 antibody revealed approximately twice as much HLA–B expression in HeLa–B27.Sv5 cells compared to
wild-type (WT) HeLa cells. C, HeLa cells process MHC class I molecules efficiently. Pulse chase analysis of endogenous MHC class I molecules
using antibody W632 followed by endoglycosidase H (Endo H) digestion revealed that MHC class I molecules mature within 1 hour. Pulse chase
of HeLa–B27.Sv5 cells using the anti-Sv5 pK antibody showed that little Endo H–resistant material was acquired during 2 hours of chase, whereas
in control HeLa–B35.Sv5 cells, rapid acquisition of Endo H resistance was observed. IP  immunoprecipitation.
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interleukin-4 and 50 ng/ml granulocyte–macrophage-colony-
stimulating factor (R&D Systems). DCs were allowed to
differentiate for 5 days and treated with 100 ng/ml lipopoly-
saccharide (LPS; Sigma). Cell lysates were analyzed by SDS-
PAGE and immunoblotted for MHC class I heavy chain (with
HC10) and for HRD1, and developed with SuperSignal Femto
chemiluminescence reagents. HRD1 and B27D values were
generated from the Integrated Density in ImageJ (National
Institutes of Health). All values were then normalized to
–actin. For quantitation of HLA–B alleles, lysates were
analyzed for HC10 reactivity and values generated as de-
scribed above.
Pulse chase analysis. Cells were serum starved for 15
minutes and labeled with 35S-Cys/Met (300 Ci) for 15 min-
utes. Radiolabel was removed and cells resuspended in D10.
For ER stress or pharmacologic treatment, drugs were added
at the point of chase. At each time point equal numbers of cells
were removed, treated with 20 mMNEM (pH 7.4) on ice for 20
minutes, lysed in 1% NP40, and immunoprecipitated for MHC
class I. Prior to resolution by nonreducing SDS-PAGE, sam-
ples were treated with endoglycosidase H (Endo H) for 1 hour
at 37°C.
RESULTS
Direct association of EDEM1 with aberrant
MHC class I conformers. To investigate the role of
EDEM1 in the processing of HLA–B27 dimers, we used
isogenic HeLa cells expressing 2 copies of either Sv5
C-terminally tagged HLA–B27 (HeLa–B27.Sv5) or Sv5
C-terminally tagged HLA–B*35:01 (HeLa–B35.Sv5) un-
der the control of the E1F promoter. The latter was
used as a control HLA–B allele that does not form
disulfide-linked dimers.
Flow cytometric analysis of HeLa–B27.Sv5 and
–B35.Sv5 with antibodies ME1 and 4E, respectively,
revealed efficient cell surface expression of these MHC
class I molecules (Figure 1A), while W632 staining
demonstrated that all lines expressed endogenous MHC
class I molecules. We assessed the amount of HLA–B
proteins expressed by HeLa compared to HeLa–B27.Sv5
by immunoblotting with HC10. Quantitative analysis
revealed approximately twice as much HLA–B expres-
sion in HeLa–B27.Sv5 cells compared to wild-type HeLa
cells (Figure 1B), consistent with the additional 2 copies
of HLA–B27. We previously showed that HLA–B27
exhibits slow maturation kinetics (23), and pulse chase
analysis of HeLa–B27.Sv5 confirmed the slow matura-
tion kinetics compared to HLA–B35, as demonstrated
by the acquisition of Endo H–resistant material within 2
hours. Pulse chase analysis of endogenous W632-
reactive MHC class I molecules in wild-type HeLa cells
(Figure 1C) and analysis of HLA–B35 demonstrated
that MHC molecules can be processed efficiently and
rapidly by HeLa cells and that the slow kinetics of
HLA–B27 are independent of cell line expression.
Next we performed experiments in which
EDEM1 expression was enhanced as well as experi-
ments in which it was inhibited, to assess its role in the
processing of HLA–B27 dimers. The HeLa–B27.Sv5 line
expresses 3 distinct dimer populations which, as we have
previously shown, correspond to dimers in different
redox states (24). Overexpression of EDEM1 resulted in
a modest reduction in the levels of all HLA–B27 dimer
populations (Figure 2A), while depletion of EDEM1
expression led to enhancement of all 3 dimer popula-
tions (Figure 2B). As both of these differences in dimer
levels were observed at steady state, we then induced ER
stress in the absence of EDEM1, using TPG. Immuno-
blotting revealed that HLA–B27 dimers were more
abundant in EDEM1-depleted cells (Figure 2B).
We used a pharmacologic approach to further
verify that EDEM1 can participate in the degradation of
aberrant HLA–B27 dimers. HLA–B27 dimers were en-
hanced after treatment with KIF, which inhibits ERAD
and the interaction of EDEM1 with the HRD1–SEL1
degradation complex (18,25,26). In addition, the dimer
complexes displayed a small increase in molecular
weight (Figure 2C), characteristic of the retention of
high-mannose groups due to the inhibition of class I
-mannosidase activity. The monomers for both HLA–
B27 and HLA–B35 were also resolved as 2 closely
migrating bands in the presence of KIF (Figure 2C),
which may represent a mannosylated heavy chain and/or
intermediates of HLA heavy chains prior to ERAD. KIF
treatment could potentially affect dimer formation by
altering the maturation rate of HLA–B27. However,
pulse chase analysis in the presence of KIF revealed no
alteration in HLA–B27 maturation rates (Figure 2C).
To determine whether EDEM1 can directly as-
sociate with different forms of HLA–B27, EDEM1-
FLAG cDNA was either transfected into HeLa–B27.Sv5
cells or cotransfected with HLA–B*27:05 cDNA into
HeLa cells. Following immunoprecipitation of EDEM1,
immunoblotting for HLA–B27 with antibody HC10
demonstrated the preferential association of HLA–B27
dimers compared to monomeric HLA–B27 (Figure 2D).
These data suggest that EDEM1 can both associate with
MHC class I dimeric heavy chains and modulate their
levels.
Misfolded MHC class I heavy chains interact
with EDEM1 in a glycan-independent manner. We next
investigated whether EDEM1 can associate directly
with misfolded monomeric heavy chains. In a cell-based
binding assay, 293T cells were cotransfected with
EDEM1-FLAG and C-terminally Sv5-tagged wild-type
HLA–B*27:05 or with similarly tagged misfolding HLA–
B27 molecules that had the conserved structural cys-
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Figure 2. Endoplasmic reticulum (ER) degradation–enhancing -mannosidase–like protein 1 (EDEM1) modulates HLA–B27 dimers. A,
Overexpression of EDEM1 can enhance HLA–B27 dimer degradation. HeLa–B27 cells were transfected with EDEM1-FLAG, lysed, and
immunoblotted for major histocompatibility complex (MHC) class I heavy chain. Arrows 1, 2, and 3 indicate HLA–B27 dimers. Lysates
immunoblotted with anti-FLAG exhibited EDEM1 expression. B, Left, Short hairpin RNA (shRNA) inhibition (knockdown [KD]) of EDEM1
expression in HeLa–B27 cells prevented HLA–B27 dimer ER-associated degradation when compared to mock transduction with a control scrambled
shRNA. Right, HLA–B27 dimers were resistant to ER stress–induced degradation following EDEM1 knockdown. C, Top, Increasing concentrations
of kifuesine (KIF) led to enhanced detection of dimers, as determined by immunoblotting of HeLa–B27.Sv5 cells; immunoblotting for GAPDH
revealed equal loading. Insert 1 demonstrates that with increasing KIF concentrations, the high molecular weight dimers exhibit small changes in
molecular weight; arrows in insert 2 indicate that at 2.5 g/ml KIF, the monomers of both HLA–B27:05 and HLA–B*35:01 can be resolved as a
doublet. Bottom, KIF did not alter the maturation rate of HLA–B27. HeLa–B27.Sv5 cells were radiolabeled and chased in the presence of KIF or
vehicle control DMSO. D, HLA–B27 ER resident dimers preferentially associate with EDEM1. Top, HeLa–B27.Sv5 cells were transfected with
EDEM1-FLAG or HeLa cells were cotransfected with HLA–B27 and EDEM1-FLAG, and cell lysates were immunoprecipitated (IP) with an
anti-FLAG tag antibody and immunoblotted for MHC class I heavy chain. Bottom, Immunoblotting of lysates with anti-FLAG from HeLa and
HeLa–B27.Sv5 cells transfected with EDEM1 revealed equal levels of EDEM1 expression. TPG  thapsigargin; Endo H  endoglycosidase H;
WT  wild-type.
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teines of the 2 domain mutated to serines at posi-
tion 101 (C101S) or 164 (C164S). The structural HLA–
B27.C101S monomer misfolds but retains the ability to
extensively dimerize, and the C164S mutant exhibits en-
hanced levels of misfolded monomer with a reduced
ability to dimerize (23). Therefore, with the use of these
mutants we could determine whether EDEM1 associates
with dimeric and/or monomeric conformations. Twenty-
four hours after transfection, 293T cells were harvested,
treated with 20 mM NEM, and lysed in 1% NP40. Lysates
were immunoprecipitated for EDEM1 using an anti-
FLAG antibody and resolved by reducing SDS-PAGE.
Immunoblotting for HLA–B27 with the anti-Sv5
pK antibody indicated that wild-type HLA–B*27:05 and
the C101S and C164S mutants could be coimmunopre-
cipitated with EDEM1 (Figure 3A). When resolved
under nonreducing conditions, fewer monomeric wild-
type HLA–B27 heavy chains interacted with EDEM1. It
is likely that this pool would contain both correctly
folded and misfolded monomers, whereas both C101S
and C164S monomer heavy chain pools would all be
classified as misfolded. Interestingly, C101S predomi-
nantly associated as a dimer with EDEM1, while C164S
exhibited an altered dimeric conformation, but could
associate with EDEM1 both as a monomer and as a
dimer (Figure 3B).
Figure 3. EDEM1 associates with dimeric and monomeric MHC class I conformers. A, MHC class I molecules are detected only when coexpressed
with EDEM1. HEK 293T cells were cotransfected with EDEM1 and HLA–B27.Sv5 with or without the misfolding mutants B27.C101S and
B27.C164S. Lysates were immunoprecipitated for anti-FLAG, resolved by reducing sodium dodecyl sulfate–polyacrylamide gell electrophoresis
(SDS-PAGE), and immunoblotted for V5 using pK antibody. B, Both monomers and dimers can be detected in association with EDEM1.
Immunoprecipitates similar to those described in A were resolved by nonreducing SDS-PAGE and immunoblotted with pK antibody. Note that
dimeric structures are preferentially detected in the presence of WT HLA–B27 and the C101S mutant. Asterisk denotes a nonspecific background
band. C, EDEM1 associates with HLA–B27 in a glycosylation-independent manner. HEK 293T cells were cotransfected with EDEM1, E493Q,
D370N, E225Q, or a triple mutant (TM) contaning all 3 mutations, along with WT HLA–B27 or a glycosylation site–deficient mutant (N86K).
Lysates were immunoprecipitated with anti-FLAG, resolved by reducing SDS-PAGE, and probed with pK antibody. D, EDEM1 was immunopre-
cipitated and Endo H digested following cotransfection with HLA–B27 in 293T cells, and immunoblotting for MHC class I heavy chain was
performed. UT  untreated; CHO  carbohydrate (see Figure 2 for other definitions).
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To determine whether the EDEM1 mannosidase-
like domain was important in HLA–B27 heavy chain
recognition, we used a series of EDEM1 mutants, i.e.,
E225Q, E493Q, and D370N, whose acidic active site
residues within the mannosidase-like domain had been
mutated to neutral amino acids that abolish glycan-
dependent substrate binding. In addition, we used a
triple mutant of this domain, E225Q/D370N/E493Q. To
further address the requirement of glycan binding, we
used a glycosylation site–deficient mutant of HLA–B27,
N86K. In a cell-based binding assay we coexpressed
wild-type EDEM1 or the 4 EDEM1 mutants with HLA–
B27 or the B27.N86K mutant. Cells were treated with
NEM, lysed in 1% NP40, and immunoprecipitated for
EDEM1. Immunoblotting for MHC class I heavy chains
demonstrated that both wild-type and N86K HLA–B27
could be coimmunoprecipitated with all EDEM1 mu-
tants (Figure 3C).
HLA–B27 dimers can be ER resident and ex-
pressed at the cell surface. To determine which pool of
dimers was associated with EDEM1, we subjected the
EDEM1-associated HLA–B27 molecules to digestion
with Endo H. Immunoblotting revealed that following
Endo H digestion, the dimeric population associating
with EDEM1 exhibited an apparent lower molecular
weight, correlating with the removal of glycans from
ER-resident dimers (Figure 3D). Furthermore, under
these experimental overexpression conditions we addi-
tionally detected monomeric HLA–B27, which was also
susceptible to Endo H digestion (Figure 3D).
The above-described results show that the
EDEM1–MHC class I interaction is not dependent on
glycosylation of the substrate or the glycan binding site
of EDEM1. They also demonstrate that EDEM1 binds
with ER-resident dimers and misfolding monomeric
heavy chains.
HLA–B27 dimer ERAD requires the XBP-1 path-
way and HRD1 and can use derlins 1 and 2. As EDEM1
is a target gene for the potent UPR transcription factor
XBP-1s (14,27), we predicted that heavy-chain dimer
degradation would require an intact XBP-1 pathway. We
transduced HeLa–B27.Sv5 cells with a lentivirus express-
ing an shRNA targeting XBP-1, and immunoblotting
revealed that in the absence of XBP-1, HLA–B27 dimers
were more prevalent (Figure 4A).
EDEM1 and HRD1 are targets for XBP-1s in-
duction (14,27), and EDEM1 can associate with the
HRD1–SEL1 degradation complex (18). We therefore
wished to confirm the role of HRD1 in HLA–B27 dimer
degradation. We hypothesized that inhibition of HRD1
expression should prevent ERAD of HLA–B27 dimers.
HeLa-B27.Sv5 cells were infected with a retrovirus
expressing an shRNA construct targeting HRD1. Immu-
noblotting for HLA–B27 dimers revealed a large accu-
mulation of dimers and larger aggregates (Figure 4A).
We then wished to determine how inhibition of XBP-1
would affect HRD1 and EDEM1 expression. XBP-1
inhibition led to a reduction in steady-state levels of
HRD1 but did not greatly affect EDEM1. We next
subjected HeLa cells that were either mock transduced
or had undergone XBP-1 inhibition to treatment with
the ER stress–inducing agent TPG. Both HRD1 and
EDEM1 could be induced with increasing concentra-
tions of TPG; however, in the absence of XBP-1, neither
of these proteins could be significantly induced (Fig-
ure 4B). Therefore, inhibition of XBP-1 can prevent
the induction of EDEM1 and HRD1 under stress con-
ditions.
To determine the physiologic significance of the
above-described pathway for HLA–B27 dimer degrada-
tion, we analyzed HLA–B27 dimer and HRD1 levels in
cells from HLA–B27–positive AS patients. Monocyte-
derived DCs from peripheral blood were stimulated with
LPS and MHC class I dimer, and HRD1 levels analyzed
by immunoblotting. Intriguingly, HRD1 levels were con-
sistently higher in patient-derived DCs compared to
DCs from HLA–B27–positive healthy controls (Figure
4C), suggesting that HRD1 may regulate HLA–B27
dimer levels in AS patient cells.
The derlin proteins have been postulated to be
part of putative degradation pores and act as adaptors
for ERAD substrates (28). Derlin 1 is involved in
glycoprotein US11–mediated retrotranslocation of mo-
nomeric MHC class I molecules (29), while derlin 2 links
EDEM1 with the ERAD p97 component. Furthermore,
derlins 1–3 can be induced by ER stress (30). As derlin
1 has a role in MHC class I ERAD and derlin 2 has been
demonstrated to associate with EDEM1, we wished to
determine whether HLA–B27 dimer degradation could
be affected by derlin 1 and/or derlin 2. We used derlin 1
and 2 green fluorescent protein fusion proteins, which
act as dominant-negative proteins for their respective
products (29). The inhibition of derlins 1 and 2 by their
respective dominant-negative proteins resulted in en-
hanced dimers (Figure 4D). Thus, HLA–B27 dimers can
be targeted for degradation via an XBP-1–dependent
pathway, and their degradation involves the E3 ubiquitin
ligase HRD1 and the putative adaptor proteins derlin 1
and/or derlin 2.
Long life of HLA–B27 heavy-chain dimers. HLA–
B27 dimers have been postulated to be pathogenic and
to participate in inflammatory arthritic disease (5). We
initially wished to determine the half-life of HLA–B27
dimers. The longevity of HLA–B27 dimers has not been
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Figure 4. X-box binding protein 1 (XBP-1), hydroxymethylglutaryl-coenzyme A reductase degradation 1 (HRD1), and derlins 1 and 2 participate
in HLA–B27 dimer degradation. A, Degradation of HLA–B27 is dependent on the XBP-1 pathway. Left, Inhibition of XBP-1 in HeLa–B27 cells
via shRNA resulted in enhanced dimerization of HLA–B27. Insert shows the dimers after longer exposure. Right, HRD1 inhibition in HeLa–B27
cells via shRNA prevented HLA–B27 dimer ER stress–induced degradation (ERAD) when compared to mock transduction with a control shRNA
(shLuc). Immunoblotting of lysates demonstrated down-regulation of HRD1. B, HRD1 and EDEM1 depend on XBP-1 for ER stress induction.
Inhibition of XBP-1 did not lead to induction of HRD1 and EDEM1 following ER stress induction with TPG compared to shLuc mock control cells.
C, Levels of HRD1- and HC10-reactive HLA–B27 dimer were quantified in both immature (I) and mature (M) dendritic cells generated from
HLA–B27–positive controls (C) and ankylosing spondylitis (AS) patients (P). HRD1 levels were elevated in dendritic cells from the AS patients.
Shaded bars represent normalized HRD1 levels; open bars represent normalized B27 dimer (D) levels. D, Derlins 1 and 2 can participate in
HLA–B27 dimer ERAD. Left, Expression of derlin 1 and derlin 2 green fluorescent protein (GFP) fusion proteins. Middle, HeLa–B27 cells were
transduced with derlin 1 and derlin 2 GFP–tagged proteins, which act as dominant-negative inhibitors of the respective derlin activities.
Immunoblotting revealed that both derlin 1 and derlin 2 could modestly enhance HLA–B27 dimer formation, leading to the enhanced detection of
dimers as highlighted by arrows 1, 2, and 3. Right, Quantitation of dimer bands 1, 2, and 3 reveals a 2–3-fold increase in their detection when derlin
1 and 2 activities are inhibited. See Figure 2 for other definitions.
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well studied, although HC10-reactive HLA–B27 dimers
have been reported to have a half-life of 2 hours (31).
Using our controlled expression system of HLA–B27 we
were able to determine the duration of all populations of
dimers.
We metabolically labeled HeLa–B27 cells for 15
minutes with 35S-Cys/Met before chasing for 0, 2, 4, 6,
and 8 hours and immunoprecipitating with the anti-Sv5
pK antibody. Pulse chase analysis revealed that dimers
were long-lived and evident up to 8 hours (Figure 5A).
To further assess the half-life of HLA–B27 dimers, we
treated cells with the protein synthesis inhibitor cyclo-
heximide (50 M) and determined dimer levels by
immunoblotting. Again this analysis revealed that HLA–
B27 dimers were extremely long-lived, with detectable
levels remaining 18 hours after cycloheximide treatment
(Figure 5B). Therefore, at steady-state levels, HLA–B27
dimers exhibit a prolonged lifetime and appear to be
resistant to steady-state degradation pathways.
Enhancement of ERAD of HLA–B27 dimers by
pharmacologic induction of the UPR. Our data indi-
cated that induction of ER stress could aid in dimer
removal and could potentially be used as a therapeutic
intervention strategy. If EDEM1 and/or other proteins
that are up-regulated during ER stress are involved in
ERAD of HLA–B27 dimers, we hypothesized that in-
duction of the UPR should enhance the removal of
HLA–B27 dimers. To test this, HeLa–B27.Sv5 cells were
incubated with pharmacologic agents known to induce
the UPR, such as TUN, TPG, and MG132 (32). Immu-
noblotting revealed significantly fewer HLA–B27 dimers
(Figure 6A), suggesting that ER stress–induced ERAD
was regulating dimer levels.
We then determined whether ER stress reduced
the half-life of dimers by performing kinetic and pulse
chase analyses. A kinetic study of the effects of these
drugs revealed initial enhanced dimerization, as might
be expected from their ability to inhibit normal folding
processes, but this was followed by dimer disappearance
(Figures 6B and C and Guiliano DB, et al: unpublished
observations). For pulse chase analysis, cells were met-
abolically labeled and at the point of chase, were incu-
bated with TUN. Following such treatment, dimers were
indeed degraded far more rapidly, disappearing within
8–12 hours posttreatment (Figure 6C). Previously, we
demonstrated that changes within the 1–2 hours of
maturation can affect the ability of MHC class I mole-
cules to dimerize (23). It was possible that dimer levels
could be modulated by the effects of these drugs on the
maturation rates of the HLA–B27 monomer, but pulse
chase analysis in the presence of TPG and TUN did not
reveal any alterations to the maturation phenotype
following ER stress induction during the first 4 hours.
However, TUN appeared to enhance the maturation
rate markedly, while TPG had little if any effect (Figure
6D). Therefore, induction of ER stress using a pharma-
cologic approach can modulate levels of aberrant mis-
folded MHC class I molecules.
DISCUSSION
In the present study we have defined a role of
EDEM1 in the degradation pathway of HLA–B27 di-
Figure 5. Half-life of HLA–B27 heavy chain dimers. A, HLA–B27 dimers have a prolonged half-life. HeLa–B27Sv5 cells were metabolically labeled,
chased, and immunopecipitated with pK antibody. HLA–B27 dimers were apparent at 8 hours of chase. B, HLA–B27 dimers have a half-life in excess
of 16 hours. HeLa–B27Sv5 cells were treated with 50 M cycloheximide, and dimer levels were detected by immunoblotting of lysates resolved by
nonreducing sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Endo H  endoglycosidase H; UT  untreated.
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meric molecules. The XBP-1–induced ERAD of HLA–
B27 dimers involves EDEM1, the E3 ubiquitin ligase
HRD1, and the adaptor proteins derlins 1 and 2 (Figure
4). EDEM1 shows specific affinity for HLA–B27 dimers
as well as binding to misfolded monomers (Figures 2
and 3).
The induction of ERAD via the UPR has been
demonstrated to lead to the degradation of misfolded
Figure 6. Incubation with unfolded protein response–inducing drugs leads to loss of HLA–B27 dimers. A, Treatment with tunicamycin
(TUN), TPG, and MG132 led to loss of HLA–B27 dimers. B, Top, Treatment with TUN and TPG resulted in disappearance of dimers after 8 hours.
Bottom, ER stress–inducing drugs exhibited a biphasic effect, with TUN and MG132 treatment leading to the accumulation of dimers up to 8 hours
and TUN treatment resulting in the appearance of glycan-free (CHO) forms of dimers. C, TUN enhances the rate of dimer degradation. Top
and middle, HLA–B27 cells were labeled with 35S-Cys/Met and then chased in the presence of 5 g/ml TUN (top) or in the absence of TUN
(middle). Cells were chased for 0, 2, 4, 13, 14, 16, and 18 hours and immunoprecipitated for MHC class I heavy chain with pK antibody. Dimers (D)
and monomers (M) are highlighted. Asterisk denotes BiP. Note that dimers were not apparent after 4 hours of chase (top). Bottom, The pres-
ence of dimers at each time point was assessed quantitatively. D, The maturation rate of HLA–B27 as determined by pulse chase analysis was not
substantially affected by ER stress–inducing drugs (TPG and TUN). See Figure 2 for other definitions.
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proteins (33). UPR-induced ERAD appears to target
misfolded polypeptides in preference to folded mono-
mers, and this could be explained in part by the activity
of EDEM1. How EDEM1 distinguishes such structures
remains unresolved, but could involve interactions with
calnexin and/or BiP. EDEM1 was originally proposed to
act on misfolding substrates through its proposed man-
nosidase activity (15–17). However, our findings demon-
strate that the mannosidase-active site of EDEM1 is not
necessary for substrate interactions (Figure 3C) and
suggest that the glycosylation status of this substrate
does not influence its interaction with EDEM1. These
results are consistent with previously reported observa-
tions on EDEM1 interactions in a study using the
misfolding 1-antitrypsin–null Hong Kong protein
model (18).
Our results strongly suggest that HLA–B27
dimers are long-lived. Relatively little is known regard-
ing the half-life and duration of such aberrant conform-
ers. It has been proposed that HC10-reactive dimers
have a half-life of2 hours (31). However, in our system
HLA–B27 expression was controlled and used a
C-terminally tagged epitope, which enabled us to per-
form an unbiased analysis of dimeric populations. It is
possible that dimer duration and expression could be
affected by additional factors. Recently, ER aminopep-
tidase 1 (ERAP-1), which trims MHC class I–associated
peptides (34), has also been found to be associated with
AS (3). The peptide trimming activity could be altered
by ERAP-1 polymorphisms associated with AS or by
increased expression levels (35), which could generate
unstable peptides similar to those observed in ERAP-1–
knockout cells (36). An altered peptide subset could lead
to MHC class I misfolding, increasing the propensity for
HLA–B27 to dimerize and potentially overload the
ERAD cell machinery. Recently, a poor supply of
peptides was postulated to participate in the expression
of cell surface HLA–B27 dimeric conformers (37). Thus,
it is entirely possible that the peptide repertoire could
participate in the expression of aberrant ER-resident or
plasma membrane–associated HLA–B27 conformers.
The present findings have 3 potentially important
implications. First, if misfolding and aggregation of
HLA–B27 cause the associated inflammatory diseases,
then they could be targeted for therapeutic intervention,
as proposed for other conformational diseases, such as
1-antitrypsin deficiency (38). HRD1 activity has been
implicated in such disorders (39), and our demonstra-
tion that HRD1 expression, and possibly activity, cor-
relates with disease suggests that this pathway may
have an important role in how these conformers are
handled in AS. Although we demonstrated that HRD1
and EDEM1 participate in the degradation of HLA–B27
dimers and that this pathway may be activated in AS, it
is possible that there are differences in these pathways
when comparing ex vivo DC–expressing physiologic
levels of MHC class I molecules versus transfected cell
lines, and this will require further investigation.
Second, EDEM1 and engagement of the HRD1–
SEL1 complex appear to be the rate-limiting steps in the
degradation of pathogenic disulfide-bonded dimers of
HLA–B27. It has previously been postulated that the
resolution of disulfide bonds of HLA–B27 homodimers
determined the rate of their degradation (31); however,
at steady state these molecules are far more long-lived
and stable than originally proposed.
Third, the degradation of HLA–B27 dimers of-
fers the potential for therapeutic targeting by manipu-
lating the ER stress response and induction of the
ERAD pathway. Our study demonstrates that the ER
stress pathway can be manipulated to modulate dimer
expression. The use of ER stress–inducing drugs high-
lights this proof-of-principle application, with dimers
becoming less apparent following the use of such ER
stress–inducing drugs (Figure 6). Pulse chase analysis
with the drugs administererd at the point of chase
demonstrated that the heavy chain can still mature
slowly and that maturation is not altered significantly to
account for the reduced detection of dimeric HLA–B27
populations (Figure 6D). Thus, the observed effects of
these drugs on dimer levels are not due to their effects
on folding. These agents should, in theory, perturb
folding and as such, cause an accumulation of dimers.
However, kinetic studies demonstrated a biphasic action
of the drugs, with a brief accumulation of dimers in the
early stages (0–8 hours) (Figure 6B), which then decline
at later time points, correlating with the induction of
HRD1 (Guiliano DB, et al: unpublished observations).
Therefore, the initial effect of ER stress–inducing drugs
is to interfere with protein folding, with the accumula-
tion of misfolding protein triggering ER stress pathways.
The spondyloarthritides have been hypothesized
to be disorders resulting from HLA–B27 misfolding,
with dimerization contributing to the disease process
(4,40). Understanding the factors that contribute to the
misfolding of HLA–B27 could have an impact on future
treatment approaches. The present findings suggest that
modulation of ER stress could offer a novel therapeutic
intervention point. Drugs modulating ER stress re-
sponses are already under clinical development and
testing for the treatment of multiple myelomas (41,42).
These could also be tested and, if effective, repurposed,
for the treatment of HLA–B27–associated diseases as
well as other disorders associated with protein misfolding.
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